Sign up to save your podcasts
Or
Share Nines Raises $16.5M in Series A Funding
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nines Raises $16.5M in Series A Funding
Nines, a Palo Alto, CA-based teleradiology company, raised $16.5M in Series A funding.
The Emergent Neuro Suite is intended for triage of cytotoxic edema, hemorrhage, and mass effect, all of which are exceptionally time sensitive.
Nines is currently in discussions with the FDA regarding the evidence that the agency will require to support a marketing application for its Emergent Neuro Suite.
The Emergent Neuro Suite is an investigational device in the US, limited by Federal law to investigational use.
It is not currently employed by the Nines teleradiology practice. | To read full story, visit https://startuparound.com/read/1574766008.778426/Nines-Raises-$16.5M-in-Series-A-Funding?ref=audio_experience
View all episodes
By Startup AroundNines, a Palo Alto, CA-based teleradiology company, raised $16.5M in Series A funding.
The Emergent Neuro Suite is intended for triage of cytotoxic edema, hemorrhage, and mass effect, all of which are exceptionally time sensitive.
Nines is currently in discussions with the FDA regarding the evidence that the agency will require to support a marketing application for its Emergent Neuro Suite.
The Emergent Neuro Suite is an investigational device in the US, limited by Federal law to investigational use.
It is not currently employed by the Nines teleradiology practice. | To read full story, visit https://startuparound.com/read/1574766008.778426/Nines-Raises-$16.5M-in-Series-A-Funding?ref=audio_experience